The management team is highly accomplished in pharmaceutical development and in creating
significant enterprise value. In particular, the CEO, Chris Prior, Ph.D., has created liquidity opportunities
with his last four companies, two M&As and two IPOs, while the CMO, Daniel Vlock, M.D., has also built
and sold a biopharm company. Together, exits achieved by these two executives exceed $1 Billion.